LRRC15 and cancer: In agreement with this, we show efficacy of our LRRC15-targeted radioimmunotheranostic platform in mouse models with LRRC15+ cancer cells (HuO9, U118MG) and with LRRC15+ murine stroma (CAF; HCC1954), leading to treatment-induced reversal of pro-tumorigenic mechanisms, modulation of immune-related pathways, and enhanced response to immune checkpoint inhibitors (ICIs).